Collegium Pharmaceutical (COLL) Income from Continuing Operations (2014 - 2026)

Collegium Pharmaceutical's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 14496000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 499.75% year-over-year to 14496000.0; the TTM figure through Mar 2026 stood at 74949000.0 (up 70.75% YoY), while the FY2025 annual figure was 62870000.0, down 9.13% from the prior year.
• Income from Continuing Operations was 14496000.0 for Q1 2026 at Collegium Pharmaceutical, down from 16963000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 31940000.0 in Q4 2023 to a low of 17426000.0 in Q1 2023.
• Historically, Income from Continuing Operations has averaged 9982882.35 across 5 years, with a median of 12536000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 183.44% in 2022, then jumped 4415.1% in 2023.
• A 5-year view of Income from Continuing Operations shows it stood at 7199000.0 in 2022, then soared by 543.67% to 31940000.0 in 2023, then tumbled by 60.75% to 12536000.0 in 2024, then surged by 35.31% to 16963000.0 in 2025, then declined by 14.54% to 14496000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 14496000.0 (Q1 2026), 16963000.0 (Q4 2025), and 31507000.0 (Q3 2025), per Business Quant data.